Description:
Background
ACZ is a reversible carbonic anhydrase enzyme inhibitor. This now generic medication has a good safety and tolerability profile, and is known to transiently enhance cerebral perfusion. Enhancing perfusion might improve tissue integrity within areas previously injured.
Technology Overview
- Patients tolerated doses of ACZ up to 4000 mg daily with tolerable side effects.
- Cerebral blow flow (CBF) of healthy controls returned to near baseline within 60 min.
- Increased CBF in MS patients remained present for up to 180 min.
- Pair-wise analysis showed significant increase in CBF at 2000 mg vs 0 mg ACZ in the cortex and deep gray matter
- Cerebral blood flow was increased in brain tissue in MS patients and these findings support further investigation of potential lesion evolution and tissue preservation/repair with cerebral hypoperfusion
Intellectual Property Status
- Patent issued - US10363245B2
- Available for licensing
Stage of Development
- Phase 1 clinical trial complete
- IND obtained for Phase 2 clinical trial
Associated Publications
- Multiple Sclerosis Journal 2014, Vol 20(3) 365-373; https://doi.org/10.1177/1352458513495936
- J of Neuroimmunology 326 (2019) 45-48; https://doi.org/10.1016/j.neuroim.2018.11.007